ImageneBio, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $800,000 | $3.5M | $9.2M | $15.6M | $31.0M |
| Research and development | $28.5M | $32.1M | $59.7M | $64.3M | $47.1M |
| Operating expenses | $49.3M | $40.5M | $84.6M | $86.5M | $65.1M |
| Operating income | -$48.5M | -$37.0M | -$75.4M | -$70.9M | -$34.1M |
| Pretax income | -$45.7M | -$36.6M | -$68.3M | -$68.8M | — |
| Income tax expense | -$350,000 | $13,000 | -$162,000 | $0 | $0 |
| Net income | -$45.3M | -$36.6M | -$68.2M | -$68.8M | -$34.1M |
| Balance Sheet | |||||
| Cash and equivalents | $94.5M | $12.1M | $119.9M | $59.9M | $232.2M |
| Current assets | $140.3M | $12.5M | $178.7M | $160.0M | $236.5M |
| Total assets | $153.0M | $15.9M | $192.1M | $172.3M | $247.9M |
| Current liabilities | $11.2M | $17.2M | $14.2M | $21.5M | $27.2M |
| Total liabilities | $19.8M | $17.4M | $22.3M | $25.3M | $40.0M |
| Stockholders' equity | $133.1M | -$160.6M | -$126.1M | $147.0M | $207.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$47.8M | -$21.3M | -$79.7M | -$74.1M | -$60.3M |
| Depreciation and amortization | $400,000 | $1.1M | $1.0M | $751,000 | $544,000 |
| Stock-based compensation | $15.4M | $0 | $7.6M | $7.5M | $5.2M |
| Capital expenditure | — | — | $414,000 | $1.4M | $1.8M |
| Free cash flow | — | — | -$80.2M | -$75.5M | -$62.0M |
| Dividends paid | — | — | — | — | $0 |
| Share repurchases | — | — | $663,000 | — | — |
| Impairments | — | — | $0 | $0 | $0 |
Shares outstanding 11.3M · Free float 55.6%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.